Reflections on the cost of "low-cost" whole genome sequencing: Framing the health policy debate

Authors

Timothy Caulfield, University of Alberta, Canada
Jim Evans, UNC School of Medicine, United States
Amy McGuire, Baylor College of Medicine, United States
Christopher McCabe, University of Alberta, Canada
Tania M. Bubela, University of Alberta, CanadaFollow
Robert Cook-Deegan, Duke University, United States
Jennifer Fishman, McGill University, Canada
Stuart Hogarth, King's College London, England
Fiona A. Miller, University of Toronto, Canada
Vardit Ravitsky, Université de Montréal, Canada

Document Type

Article

Department

Office of the Provost

Abstract

The cost of whole genome sequencing is dropping rapidly. There has been a great deal of enthusiasm about the potential for this technological advance to transform clinical care. Given the interest and significant investment in genomics, this seems an ideal time to consider what the evidence tells us about potential benefits and harms, particularly in the context of health care policy. The scale and pace of adoption of this powerful new technology should be driven by clinical need, clinical evidence, and a commitment to put patients at the centre of health care policy.

Comments

Pagination is not provided by the author/publisher. This work was published before Tania joined Aga Khan University.

Publication (Name of Journal)

PLoS Biology

DOI

10.1371/journal.pbio.1001699

Recommended Citation

Caulfield, T., Evans, J., McGuire, A., McCabe, C., Bubela, T. M., Cook-Deegan, R., Fishman, J., Hogarth, S., Miller, F. A., Ravitsky, V. (2013). Reflections on the cost of "low-cost" whole genome sequencing: Framing the health policy debate. PLoS Biology, 11(11), e1001699.
Available at: https://ecommons.aku.edu/provost_office/777

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.